|
 Britain's biggest drugmaker believes the results confirm the
potential of the once-daily single inhaler, Trelegy Ellipta, a
product it hopes will offset the impact of generic competition to
the older lung drug Advair.
Trelegy won approval based on clinical tests showing it improved
lung function and exacerbations more than AstraZeneca's
long-established two-drug inhaler Symbicort, which works in a
similar way to Advair.
The latest clinical trial, however, compares Trelegy to two more
modern two-drug combinations and was seen as a more critical test
for doctors wanting to know if the new product really delivers an
added benefit.
The IMPACT study, which involved 10,355 patients, showed Trelegy
delivered statistically significant reductions in the rate of annual
exacerbations, or attacks, compared with both Breo and Anoro, two
other relatively new GSK medicines.
[to top of second column] |
GSK and its partner Innoviva plan to submit the latest data from the
so-called IMPACT trial to regulatory authorities from the second
quarter of 2018, with the aim of expanding the indicated patient
population for Trelegy.
(Reporting by Ben Hirschler; editing by Jason Neely)
[© 2017 Thomson Reuters. All rights
reserved.] Copyright 2017 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
